Retour aux projets

13750.1;12 PFFLE-LS

Antibody-based therapy for type-2 diabetes

Résumé

Antibody-based therapy for type-2 diabetes

Textes supplémentaires

Abstract

The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.

Participants

Roger Nitsch

Kontaktperson

nitsch@bli.uzh.ch

Universität Zürich Roger Nitsch August-Forel-Strasse 1 Abteilung f. Psychiatrische Forschu 8008 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2012-02-29
Date de fin
2015-11-10
Coûts totaux approuvés
CHF 900000.00
Section
5 KTI
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T490 Biotechnology 100.0%